6 October 2020 - Hundreds of Australian patients with ovarian cancer are being given affordable access to a groundbreaking drug previously restricted to those who had failed conventional treatments such as surgery and chemotherapy.

Treasurer Josh Frydenberg announced his budget speech on Tuesday night that Lynparza, which costs more than $140,000 per course, will be available for about $41 a month for general patients and $6.60 for concession card holders.

Read Sydney Morning Herald article